LIMA/BEIJING, Aug 13 (Reuters) - A two-dose COVID-19 vaccine from China's Sinopharm was 50.4% effective in preventing infections in health workers in Peru when it was seeing a surge in cases fuelled by virus variants, and booster shots can be considered, a study found.
The vaccine, however, was 94% effective at preventing deaths after two doses, it added.
Peru has the highest pandemic death count per capita in the world, which scientists say was caused by the Lambda variant first identified late last year and made worse by a fragile healthcare system.
Peruvian health workers were vaccinated exclusively with the Sinopharm shot because that was the first to arrive in Peru and their group was the first to be vaccinated. The country has also vaccinated some people with vaccines from Pfizer and AstraZeneca.
The variant is more resistant to antibodies triggered by vaccines than the original version of the virus that emerged from Wuhan based on lab study results, Japanese researchers said in a paper ahead of peer review
In July, Israel's health ministry said in a statement that it had seen efficacy of Pfizer's vaccine drop from more than 90% to about 64% as the B.1.617.2 or Delta variant spread.
Jako zanimljiv članak od prije dva dana (to sa Izraelom je sa drugog članka). Hipotetički, zaštita od smrti 94% sa vakcinom sa obje doza, kolika je onda smrtnost bez te iste vakcine



